148930-71-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(1,3-dioxoisoindol-2-yl)cyclopropane-1-carboxylic acid is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and potential biological activities make it a promising candidate for the development of new drugs.
Used in Medicinal Chemistry Research:
1-(1,3-dioxoisoindol-2-yl)cyclopropane-1-carboxylic acid is used as a research compound to study its pharmacological properties and explore its potential applications in medicinal chemistry. This may lead to the discovery of new drugs with improved efficacy and reduced side effects.
Used in Drug Discovery:
1-(1,3-dioxoisoindol-2-yl)cyclopropane-1-carboxylic acid is used as a starting material for the development of new drugs. Its unique structural features and potential biological activities can be further modified and optimized to enhance its properties for various therapeutic applications.

Upstream product

• 85-44-9 phthalic anhydride 
• 68781-13-5 α-amino-cyclopropanecarboxylic acid hydrochloride 
• 22059-21-8 aminocyclopropane-1-carboxylic acid 

Relevant academic research and scientific papers

NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

ANTICANCER COMBINATION THERAPY

The invention describes anti-cancer therapies comprising using a SOS1 inhibitor in combination with a MEK inhibitor, each as described herein.

NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS

The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Generation and intermolecular capture of cyclopropylacyl radicals

(Chemical Equation Presented) Cyclopropylacyl radicals derived from S-cyclopropylacyl xanthates (dithiocarbonates) undergo intermolecular additions to olefins without loss of CO or ring opening. In the presence of a phenyl ring on carbon C-1 of the cyclopropane ring, loss can be made to occur in the absence of an olefinic trap. The adducts from the cyclopropylacyl radical additions are easily converted into enones by base-induced β-elimination of the xanthate group.